A consortium of investors led a $27m Series B round in Elucid.

A consortium of investors, including Biovision Ventures, MedTex Ventures, IAG Capital, Bold Brain Ventures, and BlueStone Venture Partners, led a $27m Series B round in Elucid, a company developing a novel, non-invasive medical software. "Elucid is committed to providing physicians the most rigorously validated diagnostic platform to fight cardiovascular disease. Every patient is different and needs to be treated specific to his or her individual disease. We are so proud of the remarkable work our team has accomplished and this Series B allows us to expand our commercial reach. We warmly welcome our new investors and are grateful to our existing investors for their continued support in achieving our mission," Blake Richards, Elucid Chief Executive Officer.